Search research articles
Contact Us
Filters
Showing results (1-10 of 775) with videos related to
Page
of 78
Sort By:
Hepatology (Baltimore, Md.)
|
June 29, 2007
A little orphan runs to fat: the orphan receptor small heterodimer partner as a key player in the regulation of hepatic lipid metabolism
Michael Trauner
Journal of Hepatology
|
August 19, 2020
EASL Recognition Award Recipient 2020: Prof. James L. Boyer
Michael Trauner
Gastroenterology
|
March 4, 2003
When bile ducts say NO: the good, the bad, and the ugly
Michael Trauner
Hepatology (Baltimore, Md.)
|
July 9, 2004
The nuclear bile acid receptor FXR as a novel therapeutic target in cholestatic liver diseases: hype or hope?
Michael Trauner
Journal of Hepatology
|
June 3, 2020
Effective medical treatments for PSC needed ASAP - is AESOP the answer?
Michael Trauner
Journal of Hepatology
|
June 12, 2012
EASL recognition awardee 2012: Professor Peter L.M. Jansen
Michael Trauner
Gastroenterology
|
February 22, 2011
Nuclear receptors as new perspective for the management of liver diseases
Michael Trauner, Emina Halilbasic
F1000Research
|
May 3, 2016
Recent advances in understanding and managing cholestasis
Martin Wagner, Michael Trauner
Journal of Hepatology
|
August 10, 2023
FXR agonists in NASH treatment
Luciano Adorini, Michael Trauner
Seminars in Liver Disease
|
July 21, 2021
Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities
Richard Radun, Michael Trauner
Page
of 78
Search research articles
Search
Showing results (1-10 of 775) with videos related to
Sort By:
Page
of 78
Hepatology (Baltimore, Md.)
|
June 29, 2007
A little orphan runs to fat: the orphan receptor small heterodimer partner as a key player in the regulation of hepatic lipid metabolism
Michael Trauner
Journal of Hepatology
|
August 19, 2020
EASL Recognition Award Recipient 2020: Prof. James L. Boyer
Michael Trauner
Gastroenterology
|
March 4, 2003
When bile ducts say NO: the good, the bad, and the ugly
Michael Trauner
Hepatology (Baltimore, Md.)
|
July 9, 2004
The nuclear bile acid receptor FXR as a novel therapeutic target in cholestatic liver diseases: hype or hope?
Michael Trauner
Journal of Hepatology
|
June 3, 2020
Effective medical treatments for PSC needed ASAP - is AESOP the answer?
Michael Trauner
Journal of Hepatology
|
June 12, 2012
EASL recognition awardee 2012: Professor Peter L.M. Jansen
Michael Trauner
Gastroenterology
|
February 22, 2011
Nuclear receptors as new perspective for the management of liver diseases
Michael Trauner, Emina Halilbasic
F1000Research
|
May 3, 2016
Recent advances in understanding and managing cholestasis
Martin Wagner, Michael Trauner
Journal of Hepatology
|
August 10, 2023
FXR agonists in NASH treatment
Luciano Adorini, Michael Trauner
Seminars in Liver Disease
|
July 21, 2021
Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities
Richard Radun, Michael Trauner
Page
of 78